Endokrynologia Polska · 2026
Proteomics and metabolomics reveal growth hormone deficiency-induced complement and metabolic dysregulation in post-COVID-19 condition.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bai Guirong, Xie Xiaomin, Li Shiting, Ji Wenrui, Li Huan, He Yanting, Zhang Li, Li Ling, Pei Siqi, Yang Yazhi, Wu Yawen, Ping Rui
Аннотация
INTRODUCTION: Post-COVID-19 condition (PCC) is often accompanied by endocrine and immune dysregulation. Growth hormone (GH)deficiency has been reported in PCC patients, but its systemic effects remain poorly defined.
MATERIAL AND METHODS: Eighty-eight PCC patients were classified into four groups based on GH levels (A: GH ≥ 10 ng/mL; B:5 ng/mL ≤ GH < 10 ng/mL; C: 1 ng/mL ≤ GH < 5 ng/mL; D: GH < 1 ng/mL), and insulin tolerance testing was performed to assess GH and cortisol levels. Serum samples from PCC patients were analyzed using proteomics and metabolomics, followed by correlation analyseswith GH and cortisol levels.
RESULTS: There were significant differences among the four groups in GH levels at baseline, 30, 60, 90, and 120 minutes after ITT. Similarly, cortisol levels at 30, 60, 90, and 120 minutes post ITT also showed significant differences among the four groups. Proteomic profiling identifiedsignificant alterations of proteins in complement and coagulation cascades across different GH levels. Compared with group B, groupD (GH deficiency) showed reduced expression of lipid transport proteins (such as APOB, APOH, and APOF), consistent with the lowerserum low-density lipoprotein cholesterol (LDL-C) levels observed in the GH deficiency group. Integrative analysis of comparisons amonggroups highlighted SPARCL1 as a hub protein linked to GH dysregulation, showing a critical response to declining GH. Correlation analysisalso revealed strong associations of F/GH levels with complement-related proteins and SPARCL1. Metabolomic profiling revealed that L-glutamic acid and traumatic acid were significantly elevated in group C compared with group B, with AUC values of 0.657 and 0.739,respectively, indicating that these metabolites can distinguish patients with normal GH from those with GH deficiency. In addition, tetradecanedioicacid, which was markedly increased in group C compared to group D, showed a significant positive correlation with GHlevels at multiple time points. Integrated proteomic and metabolomic analyses further demonstrated significant associations betweendifferentially abundant proteins and metabolites.
CONCLUSIONS: Our integrated proteomic-metabolomic analysis reveals that GH deficiency in PCC patients is associated with complement dysregulation, highlighting SPARCL1 as a potential biomarker of GH deficiency in PCC patients.
MATERIAL AND METHODS: Eighty-eight PCC patients were classified into four groups based on GH levels (A: GH ≥ 10 ng/mL; B:5 ng/mL ≤ GH < 10 ng/mL; C: 1 ng/mL ≤ GH < 5 ng/mL; D: GH < 1 ng/mL), and insulin tolerance testing was performed to assess GH and cortisol levels. Serum samples from PCC patients were analyzed using proteomics and metabolomics, followed by correlation analyseswith GH and cortisol levels.
RESULTS: There were significant differences among the four groups in GH levels at baseline, 30, 60, 90, and 120 minutes after ITT. Similarly, cortisol levels at 30, 60, 90, and 120 minutes post ITT also showed significant differences among the four groups. Proteomic profiling identifiedsignificant alterations of proteins in complement and coagulation cascades across different GH levels. Compared with group B, groupD (GH deficiency) showed reduced expression of lipid transport proteins (such as APOB, APOH, and APOF), consistent with the lowerserum low-density lipoprotein cholesterol (LDL-C) levels observed in the GH deficiency group. Integrative analysis of comparisons amonggroups highlighted SPARCL1 as a hub protein linked to GH dysregulation, showing a critical response to declining GH. Correlation analysisalso revealed strong associations of F/GH levels with complement-related proteins and SPARCL1. Metabolomic profiling revealed that L-glutamic acid and traumatic acid were significantly elevated in group C compared with group B, with AUC values of 0.657 and 0.739,respectively, indicating that these metabolites can distinguish patients with normal GH from those with GH deficiency. In addition, tetradecanedioicacid, which was markedly increased in group C compared to group D, showed a significant positive correlation with GHlevels at multiple time points. Integrated proteomic and metabolomic analyses further demonstrated significant associations betweendifferentially abundant proteins and metabolites.
CONCLUSIONS: Our integrated proteomic-metabolomic analysis reveals that GH deficiency in PCC patients is associated with complement dysregulation, highlighting SPARCL1 as a potential biomarker of GH deficiency in PCC patients.